Cardioprotective effect of Vedic Guard against doxorubicin-induced cardiotoxicity in rats: A biochemical, electrocardiographic, and histopathological study

ABSTRACT

Background: Vedic Guard is a polyherbal formulation used in the treatment of various ailments, however, is not scientifically assessed for its effect on doxorubicin-induced cardiotoxicity. Objective: To find out the preventive role of Vedic Guard against doxorubicin-induced myocardial toxicity in rats. Materials and Methods: Cardiotoxicity was produced by doxorubicin (15 mg/kg for 2 weeks). Vedic Guard (270 mg/kg, orally) was administered as pre-treatment for 2 weeks and then for 2 weeks alternated with doxorubicin (DXR). The general observations, mortality, histopathology, biomarker like lactate dehydrogenase (LDH), creatine phosphokinase (CPK), aspartate aminotransferase (AST), alanine transaminase (ALT), electrocardiographic (ECG) parameters, antioxidants such as glutathione (GSH), superoxide dismutase (SOD), and catalase (CAT) were monitored after 3 weeks of last dose. Results: The repeated administration of DXR causes cardiomyopathy associated with an antioxidant deficit. Pre-treatment with Vedic Guard decreases serum enzyme viz LDH, CPK, AST, and ALT levels to that of normal values. Vedic Guard significantly protected the myocardium from the toxic effect of DXR, by increasing the levels of antioxidants such as GSH, SOD, and CAT and decreased the elevated level of malondialdehyde. The study shows significant alteration of ECG pattern in DXR administered rats. The characteristic findings were elevation of ST segment, reduction in P waves, QRS complex, and R-R interval. Vedic Guard showed a protective effect against DXR-induced altered ECG pattern. It also reduced the severity of cellular damage of the myocardium confirmed by histopathology. Conclusion: The results of the present study indicated cardioprotective effect of Vedic Guard might be attributed to its antioxidant activity.

KEYWORDS

• Antioxidant
• cardioprotective
• cardiotoxicity
• doxorubicin
• vedic guard

Showing references and in-text citations exactly as published.

Cite this article

• DOI10.4103/0973-1296.111287Copy

RELATED ARTICLES

Matched on volume, issue, section and article type within Pharmacogn. Mag..

• Article · VOLUME 9, ISSUE 34Pharmacophore mapping based inhibitor selection and molecular interaction studies for identification of potential drugs on calcium activated potassium channel blockers, tamulotoxinBarani Kumar R., Xavier Suresh M. · pp. 89–95Original ArticleSame type: ArticleSame issue
• Article · VOLUME 9, ISSUE 34Development and application of a method for determination of nucleosides and nucleobases in Mactra veneriformisJing Ji, Junyang Hu, Shiyong Chen, Rui Liu, Lingchong Wang, Jianming Cheng, Hao Wu · pp. 96–102Original ArticleSame type: ArticleSame issue
• Article · VOLUME 9, ISSUE 34Simultaneous determination of 5 phenolic acids in fried Fructus xanthii from different production sites and its dispensing granules by using ultra-pressure liquid chromatographyBin Chen, Lihua Ma, Xubo Wang, Yuping Shen, Xiaobin Jia · pp. 103–108Original ArticleSame type: ArticleSame issue
• Article · VOLUME 9, ISSUE 34Antioxidant and acetylcholinesterase inhibition properties of Amorpha fruticosa L. and Phytolacca americana L.Dimitrina Zh. Zheleva-Dimitrova · pp. 109–113Original ArticleSame type: ArticleSame issue